9.2 Special Administration Routes: Epidural, Intrathecal, Ophthalmic & Intravesical Sterile Preparations

9.2 Special Administration Routes: Epidural, Intrathecal, Ophthalmic & Intravesical Sterile Preparations

---

Central Nervous System Routes: Intrathecal vs. Epidural Administration

Parenteral administration into the central nervous system (CNS) represents the highest risk tier in clinical sterile compounding. Understanding the anatomical and physiological distinctions between the epidural and intrathecal spaces is essential for clinical pharmacists.

Anatomical and Physiological Distinctions

• Epidural Space: The epidural space is a potential space situated external to the dura mater and internal to the periosteum of the vertebral canal. It contains loose adipose connective tissue, extensive venous plexuses (Batson's plexus), lymphatics, and spinal nerve roots traversing the intervertebral foramina. Medications administered epidurally diffuse across the dural sleeve into the cerebrospinal fluid (CSF) or undergo systemic vascular uptake via the epidural venous plexus. Because of vascular uptake and systemic dilution, larger drug volumes and concentrations are typically required compared to the intrathecal route.
• Intrathecal (Subarachnoid) Space: The subarachnoid space lies directly beneath the arachnoid mater and external to the pia mater, encasing the spinal cord and extending into the cerebral ventricles. It contains circulating cerebrospinal fluid. Total adult CSF volume is approximately $140\text{ to }150\,\text{mL}$, with a turnover production rate of $\sim 500\,\text{mL/day}$ ($0.35\,\text{mL/min}$). The intrathecal space lacks adipose tissue, has virtually zero cellular bioburden, possesses low endogenous protein ($15-45\,\text{mg/dL}$), and is devoid of humoral antibodies, complement proteins, or reticuloendothelial phagocytic cells. Drug solutions injected intrathecally come into immediate, unbuffered contact with vulnerable spinal cord parenchyma, unmyelinated nerve rootlets, and pial microvasculature.

---

Preservative-Free Mandates and Mechanisms of Neurotoxicity

Under no circumstances may a compounded sterile preparation containing antimicrobial preservatives, chemical stabilizers, or antioxidants be administered into the intrathecal or epidural space. Preserved commercial drug vials (e.g., bacteriostatic $0.9\%$ sodium chloride, multi-dose local anesthetics, or preserved opioid formulations) are strictly contraindicated for neuraxial delivery.

Molecular Mechanisms of Preservative Neurotoxicity

1. Benzyl Alcohol: Commonly utilized as an antimicrobial preservative at concentrations of $0.9\%$ in multi-dose injectables. When introduced into the neuraxial space, benzyl alcohol functions as a potent neurotoxin. It dissolves myelin sheath lipids, uncouples mitochondrial oxidative phosphorylation, and provokes direct axonal lysis. Intrathecal injection results in chemical arachnoiditis, myeloradiculopathy, irreversible paraplegia, and fatal toxic encephalopathy. Systemic accumulation in neonates precipitates the fatal "gasping syndrome."
2. Parabens (Methylparaben and Propylparaben): Alkyl esters of $p$-hydroxybenzoic acid used widely for broad-spectrum antifungal and antibacterial preservation. In the intrathecal environment, parabens induce severe, progressive spinal adhesive arachnoiditis characterized by dense collagenous fibrosis of the leptomeninges, vascular obliteration, nerve root tethering, and intractable chronic neuropathic pain syndromes (cauda equina syndrome).
3. Phenol and Chlorobutanol: Phenol is a known neurolytic agent used intentionally in chemical neurolysis for intractable cancer pain. Inadvertent administration of phenol-preserved medications (e.g., preserved radiocontrast agents or multi-dose injectables) into the neuraxial space causes denaturing protein necrosis, non-selective destruction of sensory and motor tracts, and permanent flaccid paralysis.
4. Antioxidants and Excipients (Sulfites, Metabisulfites, EDTA): Sodium metabisulfite and EDTA are frequently formulated into commercial epinephrine and opioid ampules. Metabisulfites cause direct neuronal vacuolation, axonal edema, and chemical meningitis. Compounding pharmacists must verify that all starting components (e.g., morphine, hydromorphone, bupivacaine, fentanyl) are labeled explicitly as "Preservative-Free" (PF) and antioxidant-free.

---

Bacterial Endotoxin Dynamics and Tolerances (USP <85>)

Bacterial endotoxins (lipopolysaccharides [LPS] from Gram-negative bacterial outer membranes) are potent pyrogenic toxins that survive standard thermal autoclaving and sterilizing $0.22\,\mu\text{m}$ filtration.

The Intrathecal Endotoxin Limit Equation

Per USP General Chapter <85> (Bacterial Endotoxins Test), the maximum permissible endotoxin limit ($L$) is calculated using the formula:

$L = \frac{K}{M}$

Where:

• $K$ is the threshold human pyrogenic dose of endotoxin per kilogram of body weight.
• $M$ is the maximum recommended human dose of the drug administered per kilogram within a single 1-hour period (assuming an average adult weight of $70\,\text{kg}$ if dosing is fixed).

The Intrathecal $K$-Value Disparity

---

Baricity and Tonicity Considerations in Intrathecal Compounding

• Cerebrospinal Fluid Density: Normal human CSF has a specific gravity of $1.0063\text{ to }1.0075$ at $37^\circ\text{C}$ (density $\approx 1.0003-1.0008\,\text{g/mL}$).
• Baricity refers to the ratio of the density of a local anesthetic solution to the density of human cerebrospinal fluid at body temperature:
  1. Isobaric Solutions (Baricity $\approx 1.000$): Formulated in $0.9\%$ sodium chloride; remains localized at the anatomical segment of spinal injection, independent of patient gravitational positioning.
  2. Hyperbaric Solutions (Baricity $> 1.000$): Formulated by admixing the active drug with $5\%\text{ to }8\%$ dextrose injection. The higher density causes the drug to sink into gravitationally dependent curves of the spine (e.g., sacral or low thoracic pools) depending on whether the patient is placed in Trendelenburg or reverse Trendelenburg positioning.
  3. Hypobaric Solutions (Baricity $< 1.000$): Formulated by diluting the drug with sterile water for injection; density is lower than CSF, causing the drug bolus to float upward against gravity within the subarachnoid column.
• Tonicity Requirements: Intrathecal solutions must remain strictly iso-osmotic (physiological target $\sim 280-300\,\text{mOsm/kg}$). Infusion of hypotonic fluids causes rapid osmotic fluid shifts into unmyelinated neuronal axons, leading to intracellular edema and cellular lysis. Hypertonic solutions extract neuronal water, precipitating cellular desiccation, membrane rupture, and irreversible axonal shear injury.

---

Ophthalmic Sterile Preparations: Intraocular vs. Topical Routes

Sterile compounding for ocular therapies bifurcates into topical surface administrations and invasive intraocular injections, each carrying radically different compounding standards.

Comparison of Ophthalmic Administration Routes

Pathogenesis of Toxic Anterior Segment Syndrome (TASS)

Toxic Anterior Segment Syndrome (TASS) is an acute, non-infectious, sterile inflammatory reaction of the anterior chamber occurring within 12 to 48 hours following intraocular surgery or injection. It is caused by chemical, particulate, or endotoxin contamination:

• Preservative Cytotoxicity: Inadvertent introduction of benzalkonium chloride (BAK) into the anterior chamber causes instantaneous lysis of corneal endothelial cells. Because the corneal endothelium does not regenerate, massive cellular death results in permanent corneal stromal edema, bullous keratopathy, trabecular meshwork sclerosis, secondary glaucoma, and irreversible visual loss.
• Endotoxin Contamination: Trace Gram-negative endotoxin residues in ophthalmic surgical fluids (such as intraocular irrigation solutions or intracameral cefuroxime/moxifloxacin) trigger an explosive local inflammatory cascade characterized by hypopyon, diffuse corneal haze, and fibrin exudation.
• USP <789> Particulate Thresholds: Light obscuration particle limits for intraocular formulations are dramatically more stringent than intravenous limits: $\le 50\text{ particles/mL} \ge 10\,\mu\text{m}$, and $\le 5\text{ particles/mL} \ge 25\,\mu\text{m}$. Particulate matter inside the eye occludes trabecular meshwork outflow and triggers granulomatous uveitis.

---

Intravesical Instillations: Mitomycin C & BCG Containment

Intravesical chemotherapy involves the direct instillation of antineoplastic or immunotherapeutic agents into the bladder cavity via a urethral Foley catheter for the management of non-muscle-invasive bladder cancer (NMIBC).

Mitomycin C Formulation and Pharmacodynamics

• Properties: Mitomycin C is an antitumor antibiotic and severe vesicant. Contact with exposed epithelium causes chemical cystitis, contact ulceration, and necrosis.
• pH-Dependent Stability and Efficacy: Mitomycin C rapidly degrades in acidic aqueous media (half-life $< 1\,\text{hour}$ at $\text{pH} < 5.5$). To optimize antineoplastic efficacy and minimize systemic urothelial reabsorption, patients undergo oral urine alkalization regimens (e.g., $1.3\,\text{g}$ oral sodium bicarbonate the night before and morning of instillation) to ensure urine $\text{pH} > 7.0$.

Bacillus Calmette-Guérin (BCG) Biosafety and Handling Protocols

Bacillus Calmette-Guérin (BCG) is a freeze-dried suspension of live attenuated Mycobacterium bovis. Because it consists of viable mycobacteria, it presents severe compounding and occupational hazards.

[Live Attenuated Mycobacterium bovis (BCG)]
                  │
                  ▼
   Prepare as a biohazard:
   ├── Class II Biological Safety Cabinet (BSC) or CACI
   ├── Away from areas where parenteral drugs are prepared
   ├── Many facilities: externally vented BSC in a negative-pressure room
                  │
                  ▼
   PROHIBITED ACTIONS:
   ├── NEVER compound in a positive-pressure LAFW
   ├── NEVER compound simultaneously with IV chemotherapy or TPN
   └── NEVER use standard alcohol rubs for spill decontamination
                  │
                  ▼
   DECONTAMINATION STANDARD:
   └── EPA-Registered Tuberculocidal Disinfectant (Bleach / Accelerated H2O2)

Crucial BCG Compounding Safeguards

1. Containment Standards: BCG labeling calls for handling it as biohazardous material, using Biosafety Level 2 (BSL-2) practices, and preparing it with aseptic technique in a biological safety cabinet. Many facilities also apply USP <800>-style containment, meaning an externally vented BSC or CACI in a negative-pressure room or C-SCA. Never use a laminar airflow workbench for BCG, because it blows air from the work zone toward the operator.
2. Separation from Parenteral Preparations: BCG labeling warns that nosocomial infections have followed parenteral drugs prepared in areas where BCG was reconstituted. Prepare BCG away from areas where parenteral drugs are compounded, and never in the same cabinet or at the same time. Contamination of an IV preparation with live Mycobacterium bovis can cause disseminated BCG infection.
3. Aerosol Prevention: Reconstitute gently, running diluent down the vial wall and following the labeling's mixing steps without vigorous shaking. Closed or vented reconstitution devices are commonly used to limit aerosols.
4. Spill Decontamination Protocol: Standard $70\%$ sterile isopropyl alcohol (IPA) has poor mycobactericidal activity and is completely ineffective against dried mycobacteria. All BCG biohazard spills must be treated with an EPA-registered tuberculocidal disinfectant (e.g., sodium hypochlorite bleach solution or stabilized hydrogen peroxide with certified mycobactericidal activity) left wet for the full tuberculocidal contact time on the product label before wiping.